Peter Hillemanns1, Francisco Garcia2, Karl Ulrich Petry3, Vladimír Dvorak4, Oliver Sadovsky5, Ole-Erik Iversen6, Mark H Einstein7. 1. Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany. Electronic address: Hillemanns.Peter@mh-hannover.de. 2. Center of Excellence in Women's Health, University of Arizona, Tucson, AZ. 3. Clinic for Gynecology, Obstetrics, and Gynecological Oncology, Clinic of the City of Wolfsburg, Wolfsburg, Germany. 4. Center of Outpatient Gynecology Clinic and Primary Care, Brno, Czech Republic. 5. private practice, Bratislava, Slovak Republic. 6. Institute of Clinical Medicine, University of Bergen and Women's Clinic, Haukeland University Hospital, Bergen, Norway. 7. Department of Obstetrics and Gynecology and Women's Health, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY.
Abstract
OBJECTIVE: The objective of the study was to investigate the efficacy and safety of hexaminolevulinate (HAL) photodynamic therapy (PDT), a novel therapy for women with cervical intraepithelial neoplasia (CIN)1/2, to define the appropriate population and endpoints for a phase 3 program. STUDY DESIGN: This was a double-blind, randomized, placebo-controlled, dose-finding study that included a total of 262 women with biopsy-confirmed CIN 1/2 based on local pathology. Patients received 1 or 2 topical treatments of HAL hydrochloride 0.2%, 1%, 5%, and placebo ointment and were evaluated for response after 3-6 months based on biopsy, Papanicolaou test, and oncogenic human papillomavirus (HPV) test. All efficacy analyses were performed on blinded central histology review to avoid interreader variability. Adverse events, blood biochemistry, and vital signs were assessed after 3 months. RESULTS: There were no statistically significant differences between placebo and either the CIN 1 or combined CIN 1/2 populations. A clear dose effect with a statistically significant response in the HAL 5% group of 95% (18/19 patients) compared to 57% (12/21 patients) in the placebo group (P < .001) was observed at 3 months in women with CIN 2, including an encouraging 83% (5/6 patients) clearance of HPV 16/18 compared to 33% (2/6 patients) in the placebo group at 6 months. The treatment was easy to use and well accepted by patients and gynecologists. Only local self-limiting adverse reactions including discharge, discomfort, and spotting were reported. CONCLUSION:HAL PDT is a novel therapy that shows promise in the treatment of CIN 2 including clearance of oncogenic HPV, but not of CIN 1. The positive risk/benefit balance makes HAL PDT a tissue-preserving alternative in women of childbearing age who wish to preserve the cervix. Confirmatory studies are planned.
RCT Entities:
OBJECTIVE: The objective of the study was to investigate the efficacy and safety of hexaminolevulinate (HAL) photodynamic therapy (PDT), a novel therapy for women with cervical intraepithelial neoplasia (CIN)1/2, to define the appropriate population and endpoints for a phase 3 program. STUDY DESIGN: This was a double-blind, randomized, placebo-controlled, dose-finding study that included a total of 262 women with biopsy-confirmed CIN 1/2 based on local pathology. Patients received 1 or 2 topical treatments of HAL hydrochloride 0.2%, 1%, 5%, and placebo ointment and were evaluated for response after 3-6 months based on biopsy, Papanicolaou test, and oncogenic human papillomavirus (HPV) test. All efficacy analyses were performed on blinded central histology review to avoid interreader variability. Adverse events, blood biochemistry, and vital signs were assessed after 3 months. RESULTS: There were no statistically significant differences between placebo and either the CIN 1 or combined CIN 1/2 populations. A clear dose effect with a statistically significant response in the HAL 5% group of 95% (18/19 patients) compared to 57% (12/21 patients) in the placebo group (P < .001) was observed at 3 months in women with CIN 2, including an encouraging 83% (5/6 patients) clearance of HPV 16/18 compared to 33% (2/6 patients) in the placebo group at 6 months. The treatment was easy to use and well accepted by patients and gynecologists. Only local self-limiting adverse reactions including discharge, discomfort, and spotting were reported. CONCLUSION:HAL PDT is a novel therapy that shows promise in the treatment of CIN 2 including clearance of oncogenic HPV, but not of CIN 1. The positive risk/benefit balance makes HAL PDT a tissue-preserving alternative in women of childbearing age who wish to preserve the cervix. Confirmatory studies are planned.
Authors: Shahid Ali Siddiqui; Shaista Siddiqui; M A Bilal Hussain; Shakir Khan; Hui Liu; Kafil Akhtar; Syed Abrar Hasan; Ibne Ahmed; Srivalleesha Mallidi; Amjad P Khan; Filip Cuckov; Colin Hopper; Stephen Bown; Jonathan P Celli; Tayyaba Hasan Journal: Photodiagnosis Photodyn Ther Date: 2022-03-31 Impact factor: 3.577
Authors: Henriëtte S de Bruijn; Sander Brooks; Angélique van der Ploeg-van den Heuvel; Timo L M Ten Hagen; Ellen R M de Haas; Dominic J Robinson Journal: PLoS One Date: 2016-02-12 Impact factor: 3.240
Authors: Waleska K Martins; Renata Belotto; Maryana N Silva; Daniel Grasso; Maynne D Suriani; Tayná S Lavor; Rosangela Itri; Mauricio S Baptista; Tayana M Tsubone Journal: Front Oncol Date: 2021-01-20 Impact factor: 6.244
Authors: Michelle B Shin; Gui Liu; Nelly Mugo; Patricia J Garcia; Darcy W Rao; Cara J Bayer; Linda O Eckert; Leeya F Pinder; Judith N Wasserheit; Ruanne V Barnabas Journal: Front Public Health Date: 2021-07-01
Authors: Karoliina Tainio; Antonios Athanasiou; Kari A O Tikkinen; Riikka Aaltonen; Jovita Cárdenas; Sivan Glazer-Livson; Maija Jakobsson; Kirsi Joronen; Mari Kiviharju; Karolina Louvanto; Sanna Oksjoki; Riikka Tähtinen; Seppo Virtanen; Pekka Nieminen; Maria Kyrgiou; Ilkka Kalliala Journal: BMJ Date: 2018-02-27
Authors: Lucimara R Carobeli; Lyvia E de F Meirelles; Gabrielle M Z F Damke; Edilson Damke; Maria V F de Souza; Natália L Mari; Kayane H Mashiba; Cristiane S Shinobu-Mesquita; Raquel P Souza; Vânia R S da Silva; Renato S Gonçalves; Wilker Caetano; Márcia E L Consolaro Journal: Pharmaceutics Date: 2021-12-02 Impact factor: 6.321
Authors: Andrej Cokan; Maja Pakiž; Tamara Serdinšek; Andraž Dovnik; Tatjana Kodrič; Alenka Repše Fokter; Rajko Kavalar; Igor But Journal: J Clin Med Date: 2021-12-10 Impact factor: 4.241